| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10004783 | HBV | ENSG00000116329.12 | protein_coding | OPRD1 | No | No | 4985 | P41143 |
| TVIS30074531 | HIV | ENSG00000116329.12 | protein_coding | OPRD1 | No | No | 4985 | P41143 |
| TVIS30022908 | HIV | ENSG00000116329.12 | protein_coding | OPRD1 | No | No | 4985 | P41143 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | OPRD1 |
|---|---|
| DrugBank ID | DB06230 |
| Drug Name | Nalmefene |
| Target ID | BE0000420 |
| UniProt ID | P41143 |
| Regulation Type | antagonist |
| PubMed IDs | 15956985; 25187751; 27842940 |
| Citations | Ingman K, Hagelberg N, Aalto S, Nagren K, Juhakoski A, Karhuvaara S, Kallio A, Oikonen V, Hietala J, Scheinin H: Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing. Neuropsychopharmacology. 2005 Dec;30(12):2245-53.@@Paille F, Martini H: Nalmefene: a new approach to the treatment of alcohol dependence. Subst Abuse Rehabil. 2014 Aug 8;5:87-94. doi: 10.2147/SAR.S45666. eCollection 2014.@@Mann K, Torup L, Sorensen P, Gual A, Swift R, Walker B, van den Brink W: Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy. Eur Neuropsychopharmacol. 2016 Dec;26(12):1941-1949. doi: 10.1016/j.euroneuro.2016.10.008. Epub 2016 Nov 12. |
| Groups | Approved; Investigational; Withdrawn |
| Direct Classification | Phenanthrenes and derivatives |
| SMILES | OC1=CC=C2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](OC1=C24)C(=C)CC[C@@]35O |
| Pathways | |
| PharmGKB | |
| ChEMBL | CHEMBL982 |
